Ana
Alfonso Piérola
Investigadora Consultora
Argitalpenak (50) Ana Alfonso Piérola argitalpenak
2024
-
Epigenetic-based differentiation therapy for Acute Myeloid Leukemia
Nature Communications, Vol. 15, Núm. 1
-
Myelodysplastic neoplasms
Medicina Clinica, Vol. 162, Núm. 2, pp. 77-82
-
Single-cell transcriptional profile of CD34+ hematopoietic progenitor cells from del(5q) myelodysplastic syndromes and impact of lenalidomide
Nature Communications, Vol. 15, Núm. 1
-
Targeting CD38 with isatuximab and a novel CD38/CD3×CD28 trispecific T-cell engager in older patients with acute myeloid leukemia
Blood Advances
2023
-
A sex-informed approach to improve the personalised decision making process in myelodysplastic syndromes: a multicentre, observational cohort study
The Lancet Haematology, Vol. 10, Núm. 2, pp. e117-e128
-
CAR-T cell therapy for multiple myeloma: a practical toolkit for treatment in Brazil
Hematology, Transfusion and Cell Therapy, Vol. 45, Núm. 2, pp. 266-274
-
Integrated flow cytometry and sequencing to reconstruct evolutionary patterns from dysplasia to acute myeloid leukemia
Blood Advances, Vol. 7, Núm. 1, pp. 167-173
-
Optimization of universal allogeneic CAR-T cells combining CRISPR and transposon-based technologies for treatment of acute myeloid leukemia
Frontiers in Immunology, Vol. 14
-
Phase 1 study of JNJ-64619178, a protein arginine methyltransferase 5 inhibitor, in patients with lower-risk myelodysplastic syndromes
Leukemia Research, Vol. 134
-
Severe laryngeal edema after CAR-T cell treatment in a patient with multiple myeloma: a case report
Clinical Case Reports, Vol. 11, Núm. 6, pp. e7281
-
Uncovering perturbations in human hematopoiesis associated with healthy aging and myeloid malignancies at single-cell resolution
eLife, Vol. 12
2022
-
Author Correction: Stem cell architecture drives myelodysplastic syndrome progression and predicts response to venetoclax-based therapy (Nature Medicine, (2022), 28, 3, (557-567), 10.1038/s41591-022-01696-4)
Nature Medicine
-
CAR density influences antitumoral efficacy of BCMA CAR T cells and correlates with clinical outcome
Science Advances, Vol. 8, Núm. 39
-
Prognostic impact of micromegakaryocytes in primary myelodysplastic syndromes
Leukemia and Lymphoma, Vol. 63, Núm. 5, pp. 1227-1235
-
Stem cell architecture drives myelodysplastic syndrome progression and predicts response to venetoclax-based therapy
Nature Medicine, Vol. 28, Núm. 3, pp. 557-567
-
The transcription factor DDIT3 is a potential driver of dyserythropoiesis in myelodysplastic syndromes
Nature Communications, Vol. 13, Núm. 1
-
The transcriptomic landscape of elderly acute myeloid leukemia identifies B7H3 and BANP as a favorable signature in high-risk patients
Frontiers in Oncology, Vol. 12
-
Updates on the Management of Acute Myeloid Leukemia
Cancers, Vol. 14, Núm. 19
2021
-
Current therapy of the patients with mds: Walking towards personalized therapy
Journal of Clinical Medicine, Vol. 10, Núm. 10
-
Phase I First-in-Human Dose Escalation Study of the oral SF3B1 modulator H3B-8800 in myeloid neoplasms
Leukemia, Vol. 35, Núm. 12, pp. 3542-3550